Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N. Fujiwara Y, et al. Among authors: kitano s. Cancer Chemother Pharmacol. 2016 Aug;78(2):281-8. doi: 10.1007/s00280-016-3085-8. Epub 2016 Jun 16. Cancer Chemother Pharmacol. 2016. PMID: 27312735 Clinical Trial.
Biomarkers for Immune Checkpoint Inhibitors in Melanoma.
Kitano S, Nakayama T, Yamashita M. Kitano S, et al. Front Oncol. 2018 Jul 18;8:270. doi: 10.3389/fonc.2018.00270. eCollection 2018. Front Oncol. 2018. PMID: 30073150 Free PMC article. Review.
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Ebata T, Shimizu T, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Koyama T, Sato N, Nakai K, Inatani M, Yamamoto N. Ebata T, et al. Among authors: kitano s. Invest New Drugs. 2020 Apr;38(2):468-477. doi: 10.1007/s10637-019-00787-3. Epub 2019 May 24. Invest New Drugs. 2020. PMID: 31124055 Free PMC article. Clinical Trial.
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.
Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T. Shitara K, et al. Among authors: kitano s. J Immunother Cancer. 2019 Jul 24;7(1):195. doi: 10.1186/s40425-019-0677-y. J Immunother Cancer. 2019. PMID: 31340866 Free PMC article. Clinical Trial.
1,210 results